Navigantis is developing a surgical robot designed to treat a range of neurovascular conditions, including acute ischemic stroke. | Supply: Navigantis
Sufferers presenting with acute ischemic stroke undergo diagnostic cerebral angiography, followed by minimally invasive treatments including embolization of brain tumors and mechanical thrombectomy to restore blood flow.
As Navigantis’ CEO, Mor Dayan underscored the significance of this milestone, emphasizing its role in furthering the company’s mission to revolutionize interventional neurovascular treatments through innovative robotic procedures.
“The Vasco robotic platform holds the key to revolutionizing complex and time-critical neurovascular procedures, ultimately resulting in improved patient outcomes and optimized procedural efficiency.” “This marks a significant milestone towards revolutionizing robotic telesurgery for stroke patients, potentially slashing response times and ensuring timely access to life-saving care.”
Effective treatment of neurovascular disorders demands prompt and precise intervention.
A person in the United States has a stroke. Every 40 seconds, they are the primary reason for the inability to work efficiently.
If someone receives medical treatment (MT) within two hours of symptom onset, they have a 90% chance of regaining independence. After six hours, the quantity has decreased to 30% of its original level.
These findings underscore the importance of ensuring that processes are meticulously scheduled and thoroughly accessible, thereby reinforcing the need for meticulous planning and execution. Currently hindered by a shortage of qualified neuro-interventionalists and limited access beyond urban perimeters.
Despite advancements in stroke treatment methods, numerous individuals still experience delayed access to timely acute stroke interventions.
Navigantis pioneers groundbreaking advancements in minimally invasive surgery.
Navigantis has pioneered the development of an innovative interventional robotic platform, empowering precise execution of neurovascular procedures across a broad range of indications, including the timely treatment of acute ischemic stroke patients in 2022. Vasco is an investigational system undergoing rigorous scientific analysis outside of the U.S. It is not permitted for business use in any jurisdiction, including the U.S.
As endovascular procedures utilizing fluoroscopy for guidance continue to increase in frequency and complexity to treat neurovascular disorders, minimizing radiation exposure becomes increasingly crucial to ensure patient safety and reduce long-term health risks. The application of robotics in interventional procedures is expected to lead to a significant reduction.
“These initial successful robotic interventions represent a crucial milestone on the path towards tackling more complex neurovascular disorders,” said Professor Kim.
The corporation has built upon its prior success in first-in-human trials conducted in 2022, where medical professionals leveraged an earlier version of VASCO to expedite the robotic treatment of liver tumours through embolization procedures.
By mid-2024, Navigantis successfully secured a substantial $12 million Collection A funding round, marking a significant milestone for the company. Funds derived from the financing may facilitate the ongoing development and evaluation of a robotic system designed to deliver VASCO during FIH scientific trials for neurovascular procedures, thereby supporting its continued growth.
The Navigantis team contributes to the Society of Robotic Surgery. The founding team comprises Hyosig Kang, co-founder and Chief Technology Officer (CTO); Mor Dayan, co-founder and Chief Executive Officer (CEO); and Marc Camprubí Artal, Head of Operations. | Supply: Navigantis through
